WHWK (Whitehawk Therapeutics) FFO


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $4.16
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $4.16 is trading 1440.7% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • FFO:
  • GF Value™: $0.27 vs. price of $4.16 (1440.7% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.16
Price
$0.27
GF Value